Theragnostics for tumor and plaque angiogenesis with perfluorocarbon nanoemulsions

Angiogenesis

Volumn 13, Issue 2, 2010, Pages 189-202

  Lanza, G M ^a   Winter, P M ^a   Caruthers, S D ^a   Hughes, M S ^a   Hu, Grace ^a   Schmieder, A H ^a   Wickline, S A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Drug delivery; Fumagillin; Molecular imaging; MRI; Nanoparticles; Nuclear; Perfluorocarbon; Theragnostic; Ultrasound

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ARGINYLGLYCYLASPARTIC ACID; ATORVASTATIN; DOXORUBICIN; FLUOROCARBON; FLUORODEOXYGLUCOSE F 18; FUMAGILLIN; FUMAGILLOL CHLOROACETYLCARBAMATE; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE DERIVATIVE; NANOPARTICLE; PACLITAXEL; RAPAMYCIN; SORAFENIB; SUNITINIB; TECHNETIUM 99M; VITRONECTIN RECEPTOR;

ANTIANGIOGENIC THERAPY; ATAXIA; ATHEROSCLEROSIS; BIOCHEMISTRY; BREAST CANCER; CANCER SURVIVAL; CELL SURFACE; CONTRAST ENHANCEMENT; DIPLOPIA; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; ECHOGRAPHY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MOLECULAR IMAGING; NANOEMULSION; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NYSTAGMUS; PARTICLE SIZE; PATHOLOGICAL ANATOMY; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SARCOMA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; WEAKNESS;

ANIMALS; ATHEROSCLEROSIS; DIAGNOSTIC IMAGING; EMULSIONS; FLUOROCARBONS; HUMANS; NANOPARTICLES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 77955653139     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10456-010-9166-0     Document Type: Review

References (105)

1. J Folkman 1971 Tumor angiogenesis: therapeutic implications N Engl J Med 285 1182 1186 4938153
2. N Ferrara, et al. 2005 Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy Biochem Biophys Res Commun 333 328 335 15961063
3. MH Cohen, et al. 2007 FDA drug approval summary: bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer Oncologist 12 713 718 17602060
4. MH Cohen, et al. 2007 FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer Oncologist 12 356 361 17405901
5. L Lang 2008 FDA approves sorafenib for patients with inoperable liver cancer Gastroenterology 134 379
6. EP Rock, et al. 2007 Food and Drug Administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma Oncologist 12 107 113 17227905
7. FA Eskens J Verweij 2006 The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review Eur J Cancer 42 3127 3139 17098419
8. HM Verheul HM Pinedo 2007 Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition Nat Rev Cancer 7 475 485 17522716
9. 64Cu-labeled RGD peptide Bioconjug Chem 15 41 49 14733582
10. 99mTc-labeled cyclic RGD tetramer for noninvasive imaging integrin alpha(v)beta3-positive breast cancer Bioconjug Chem 18 438 446 17341108
11. LJ Wilmes, et al. 2007 AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging Magn Reson Imaging 25 319 327 17371720
12. G Liu, et al. 2005 Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study J Clin Oncol 23 5464 5473 16027440
13. MO Leach, et al. 2005 The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations Br J Cancer 92 1599 1610 15870830
14. N Hylton 2006 Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker J Clin Oncol 24 3293 3298 16829653 (Pubitemid 46622069)
15. S Flacke, et al. 2001 A novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques Circulation 104 1280 1285 11551880
16. PM Winter, et al. 2003 Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 Tesla magnetic resonance imaging Cancer Res 63 5838 5843 14522907
17. 3-targeted paramagnetic nanoparticles Magn Reson Med 53 621 627 15723405
18. DA Sipkins, et al. 1998 Detection of tumor angiogenesis in vivo by alpha v beta 3-targeted magnetic resonance imaging Nat Med 4 623 626 9585240
19. WJ Mulder, et al. 2005 MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle FASEB J 19 2008 2010 16204353
20. WJ Mulder, et al. 2006 Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging NMR Biomed 19 142 164 16450332
21. WJ Mulder, et al. 2007 Early in vivo assessment of angiostatic therapy efficacy by molecular MRI FASEB J 21 378 383 17202248
22. JC Frias, et al. 2004 Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques J Am Chem Soc 126 16316 16317 15600321
23. M Krafft 2001 Fluorocarbons and fluorinated amphiphiles in drug delivery and biomedical research Adv Drug Del Rev 47 209 228
24. M De Nichilo, et al. 1993 Granulocyte-macrophage and macrophage colony-stimulating factors differentially regulate alpha v integrin expression on cultured human macrophages Proc Natl Acad Sci USA 90 2517 2521 7681600
25. O Helluin, et al. 2000 The activation state of alpha v beta 3 regulates platelet and lymphocyte adhesion to intact and thrombin-cleaved osteopontin J Biol Chem 275 18337 18343 10751402
26. H Itoh, et al. 1997 The role of integrins in saphenous vein vascular smooth muscle cell migration J Vasc Surg 25 1061 1069 9201167
27. F Carreiras, et al. 1996 Expression and localization of alpha v integrins and their ligand vitronectin in normal ovarian epithelium and in ovarian carcinoma Gynecol Oncol 62 260 267 8751559
28. T Kageshita, et al. 2000 Differential clinical significance of alpha(v)Beta(3) expression in primary lesions of acral lentiginous melanoma and of other melanoma histotypes Int J Cancer 89 153 159 10754493
29. R Weissleder, et al. 2001 Size optimization of synthetic graft copolymers for in vivo angiogenesis imaging Bioconjug Chem 12 213 219 11312682
30. E Ruoslahti 1988 Fibronectin and its receptors Annu Rev Biochem 57 375 413 2972252
31. MM Sadeghi, et al. 2004 Detection of injury-induced vascular remodeling by targeting activated alphavbeta3 integrin in vivo Circulation 110 84 90 15210600
32. RF Mattrey 1994 The potential role of perfluorochemicals (PFCs) in diagnostic imaging Artif Cells Blood Substit Immobil Biotechnol 22 295 313 8087248
33. R Mattrey, et al. 1982 Perfluoroctylbromide: a liver/spleen = specific and tumor-imaging ultrasound contrast material Radiology 145 759 762 7146409
34. G Lanza, et al. 1996 A novel site-targeted ultrasonic contrast agent with broad biomedical application Circulation 94 3334 3340 8989148
35. G Lanza, et al. 1998 In vitro characterization of a novel, tissue-targeted ultrasonic contrast system with acoustic microscopy J Acoust Soc Am 104 3665 3672 9857523
36. CS Hall, et al. 2000 Experimental determination of phase velocity of perfluorocarbons: applications to targeted contrast agents IEEE Trans Ultrason Ferroelec Freq Contr 47 75 84
37. JN Marsh, et al. 2002 Improvements in the ultrasonic contrast of targeted perfluorocarbon nanoparticles using an acoustic transmission line model IEEE Trans Ultrason Ferroelectr Freq Control 49 29 38 11833889
38. C Hall, et al. 2001 Temperature dependence of ultrasonic enhancement with a site-targeted contrast agent J Acous Soc AM 110 1677 1684
39. MS Hughes, et al. 2007 Properties of an entropy-based signal receiver with an application to ultrasonic molecular imaging J Acoust Soc Am 121 3542 3557 17552706
40. MS Hughes, et al. 2009 Application of Renyi entropy for ultrasonic molecular imaging J Acoust Soc Am 125 3141 3145 19425656
41. PM Winter, et al. 2003 Improved molecular imaging contrast agent for detection of human thrombus Magn Reson Med 50 411 416 12876719
42. P Winter, et al. 2005 Improved paramagnetic chelate for molecular imaging with MRI J Magn Magn Mater 293 540 545
43. P Bachert 1998 Pharmacokinetics using fluorine NMR in vivo Prog Nucl Magn Reson Spectrosc 33 1 56
44. 19F-MRS studies of fluorinated drugs in humans Adv Drug Deliv Rev 41 55 74 10699305
45. MM Kaneda, et al. 2009 Perfluorocarbon nanoemulsions for quantitative molecular imaging and targeted therapeutics Ann Biomed Eng 37 1922 1933 19184435
46. GM Lanza, et al. 1996 A novel site-targeted ultrasonic contrast agent with broad biomedical application Circulation 95 3334 3340
47. 19F MR imaging with a novel fibrin-targeted nanoparticulate contrast agent Proc Int Soc Magn Reson Med 8 465
48. 19F nanoparticles Magn Reson Med 52 1255 1262 15562481
49. 19F magnetic resonance to augment molecular imaging with paramagnetic perfluorocarbon nanoparticles at 1.5 Tesla Invest Radiol 41 305 312 16481914
50. AM Neubauer, et al. 2007 Fluorine cardiovascular magnetic resonance angiography in vivo at 1.5 T with perfluorocarbon nanoparticle contrast agents J Cardiovasc Magn Reson 9 565 573 17365236
51. EA Waters, et al. 2008 Detection and quantification of angiogenesis in experimental valve disease with integrin-targeted nanoparticles and 19-fluorine MRI/MRS J Cardiovasc Magn Reson 10 43 18817557
52. 19F diffusion weighted MR spectroscopy Magn Reson Med 60 1232 1236 18956417
53. R Haubner, et al. 2001 Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics J Nucl Med 42 326 336 11216533
54. R Haubner, et al. 1999 Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting J Nucl Med 40 1061 1071 10452325
55. ML Janssen, et al. 2002 Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model Cancer Res 62 6146 6151 12414640
56. 125I-radiolabeled bitistatin as potential agents for targeting alpha v beta 3 integrins in tumor angiogenesis Bioconjug Chem 15 988 996 15366951
57. 18F-labeled PEGylated RGD peptide Eur J Nucl Med Mol Imaging 31 1081 1089 15118844 (Pubitemid 39050174)
58. 125I-labeled RGD peptide are improved by PEGylation Nucl Med Biol 31 11 19 14741566
59. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis Nucl Med Biol 31 179 189 15013483 (Pubitemid 38315112)
60. 111In complexes of a DOTA-conjugated integrin alpha v beta 3 receptor antagonist: different but biologically equivalent Bioconjug Chem 15 235 241 15025518
61. G Kong, et al. 2000 Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size Cancer Res 60 4440 4445 10969790
62. PM Winter, et al. 2003 Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles Circulation 108 2270 2274 14557370
63. PM Winter, et al. 2008 Minute dosages of alpha(nu)beta3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits FASEB J 22 2758 2767 18362202
64. P Winter, et al. 2008 Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis J Am Coll Cardiol Img 1 624 634
65. AH Schmieder, et al. 2008 Three-dimensional MR mapping of angiogenesis with {alpha}5{beta}1({alpha}{nu}{beta}3)-targeted theragnostic nanoparticles in the MDA-MB-435 xenograft mouse model FASEB J 22 4179 4189 18697838
66. G Hu, et al. 2007 Imaging of Vx-2 rabbit tumors with alpha(nu)beta3- integrin-targeted 111In nanoparticles Int J Cancer 120 1951 1957 17278104
67. M Lijowski, et al. 2008 High sensitivity: high-resolution SPECT-CT/MR molecular imaging of angiogenesis in the Vx2 model Invest Radiol 43 100 111
68. GM Lanza, et al. 2002 Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis Circulation 106 2842 2847 12451012
69. N Soman, et al. 2008 Synthesis and characterization of stable fluorocarbon nanostructures as drug delivery vehicles for cytolytic peptides Nano Lett 8 1131 1136 18302330
70. KC Crowder, et al. 2005 Sonic activation of molecularly-targeted nanoparticles accelerates transmembrane lipid delivery to cancer cells through contact-mediated mechanisms: implications for enhanced local drug delivery Ultrasound Med Biol 31 1693 1700 16344131
71. T Cyrus, et al. 2008 Intramural delivery of rapamycin with alphavbeta3-targeted paramagnetic nanoparticles inhibits stenosis after balloon injury Arterioscler Thromb Vasc Biol 28 820 826 18292395
72. P Winter, et al. 2006 Endothelial alpha(nu)beta(3)-Integrin targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis Arterioscler Thromb Vasc Biol 26 2103 2109 16825592
73. N Soman, et al. 2009 A platform of molecularly targeted nanostructures for anticancer therapy with cytolytic peptides J Clin Invest 119 2830 2842 19726870
74. J Marsh, et al. 2007 Fibrin-targeted perfluorocarbon nanoparticles for targeted thrombolysis Nanomedicine 2 533 543 17716136
75. S Liu, et al. 1998 Structure of human methionine aminopeptidase-2 complexed with fumagillin Science 282 1324 1327 9812898
76. N Sin, et al. 1997 The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2 Proc Natl Acad Sci USA 94 6099 6103 9177176
77. G Bergers, et al. 1999 Effects of angiogenesis inhibitors on multistage carcinogenesis in mice Science 284 808 812 10221914
78. V Castronovo D Belotti 1996 TNP-470 (AGM-1470): mechanisms of action and early clinical development Eur J Cancer 32A 2520 2527 9059342
79. H Konno, et al. 1996 Efficacy of an angiogenesis inhibitor, TNP-470, in xenotransplanted human colorectal cancer with high metastatic potential Cancer 77 1736 1740 8608571
80. S Shusterman, et al. 2001 The angiogenesis inhibitor tnp-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease Clin Cancer Res 7 977 984 11309349
81. P Bhargava, et al. 1999 A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer Clin Cancer Res 5 1989 1995 10473076
82. AP Kudelka, et al. 1998 Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470 N Engl J Med 338 991 992 9527612
83. AP Kudelka, et al. 1997 A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix Clin Cancer Res 3 1501 1505 9815836
84. CJ Logothetis, et al. 2001 Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer Clin Cancer Res 7 1198 1203 11350884
85. R Offodile, et al. 1999 Regression of metastatic breast cancer in a patient treated with the anti-angiogenic drug TNP-470 Tumori 85 51 53 10228498
86. AH Schmieder, et al. 2005 Molecular MR imaging of melanoma angiogenesis with alpha (v) beta (3)-targeted paramagnetic nanoparticles Magn Reson Med 53 621 627 15723405
87. S Kim, et al. 2000 Regulation of integrin alpha v beta 3-mediated endothelial cell migration and angiogenesis by integrin alpha 5 beta1 and protein kinase A J Biol Chem 275 33920 33928 10944524
88. N Boudreau J Varner 2004 The homeobox transcription factor Hox D3 promotes integrin alpha 5 beta 1 expression and function during angiogenesis J Biol Chem 279 4862 4868 14610084
89. PR Moreno, et al. 2004 Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability Circulation 110 2032 2038 15451780
90. PR Moreno, et al. 2006 Neovascularization in human atherosclerosis Circulation 113 2245 2252 16684874
91. R Virmani, et al. 2005 Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage Arterioscler Thromb Vasc Biol 25 2054 2061 16037567
92. T Bjornheden, et al. 1999 Evidence of hypoxic areas within the arterial wall in vivo Arterioscler Thromb Vasc Biol 19 870 876 10195911
93. JJ Boyle, et al. 2000 Expression of angiogenic factor thymidine phosphorylase and angiogenesis in human atherosclerosis J Pathol 192 234 242 11004701
94. JJ Khatri, et al. 2004 Vascular oxidant stress enhances progression and angiogenesis of experimental atheroma Circulation 109 520 525 14744973
95. OJ de Boer, et al. 1999 Leucocyte recruitment in rupture prone regions of lipid-rich plaques: a prominent role for neovascularization? Cardiovas Res 41 443 449
96. F Kolodgi, et al. 2007 Eliminating plaque angiogenesis: reply J Am Coll Cardiol 50 1521
97. R Khurana, et al. 2005 Role of angiogenesis in cardiovascular disease: a critical appraisal Circulation 112 1813 1824 16172288
98. RK Jain, et al. 2007 Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: a potential strategy for plaque stabilization Nat Clin Pract Cardiovasc Med 4 491 502 17712362
99. RC Pasternak, et al. 2002 ACC/AHA/NHLBI clinical advisory on the use and safety of statins Circulation 106 1024 1028 12186811
100. J Girona, et al. 1999 Simvastatin decreases aldehyde production derived from lipoprotein oxidation Am J Cardiol 83 846 851 10190397
101. M Kimura, et al. 1997 Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats Arterioscler Thromb Vasc Biol 17 1521 1526 9301630
102. BA Verhoeven, et al. 2006 Statin treatment is not associated with consistent alterations in inflammatory status of carotid atherosclerotic plaques: a retrospective study in 378 patients undergoing carotid endarterectomy Stroke 37 2054 2060 16809559
103. U Laufs, et al. 1998 Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors Circulation 97 1129 1135 9537338
104. GK Sukhova, et al. 2002 Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol Arterioscler Thromb Vasc Biol 22 1452 1458 12231565
105. M Koutouzis, et al. 2007 Statin treated patients have reduced intraplaque angiogenesis in carotid endarterectomy specimens Atherosclerosis 192 457 463 17335827